Ahead 300

The Ahead 300 is a portable, non-invasive device intended as an adjunctive aid for clinicians evaluating patients (ages 18-85, GCS 13-15) with recent closed head injuries, utilizing frontal electroencephalography (EEG) and quantitative EEG (QEEG) analysis to provide a structural injury classification and an EEG Brain Function Index. It aims to improve diagnostic accuracy and inform decisions regarding head CT scans by integrating these EEG-derived metrics with standalone cognitive performance tests and standardized clinical assessment tools.

The Ahead 300 is a portable, non-invasive, point-of-care device designed to aid in the evaluation of patients aged 18-85 years who have sustained a closed head injury within 72 hours and present with a Glasgow Coma Scale (GCS) score of 13-15. It functions as an adjunct to standard clinical practice, particularly when considering the need for a head CT scan, by analyzing brain electrical activity recorded via electroencephalography (EEG) from frontal locations on the patient's forehead. The device calculates and displays standard quantitative EEG (QEEG) parameters, including Absolute and Relative Power, Asymmetry, Coherence, and Fractal Dimension, which are then used by an algorithm to provide a structural injury classification (Negative, Positive, or Equivocal) regarding the likelihood of a structural brain injury visible on a CT scan. The Ahead 300 represents an evolution of the Ahead 200, incorporating improved accuracy and additional functionalities from other predicate devices. Beyond structural injury classification, the Ahead 300 offers several other capabilities: it provides an EEG Brain Function Index (BFI) for the statistical evaluation of brain function, which scales with the severity of functional impairment. It also includes quantitative measures of cognitive performance to assess an individual's cognitive functioning level and stores electronic versions of standardized clinical assessment tools; these cognitive and assessment tool features are standalone and do not interact with other device measures. Clinical validation trials demonstrated that the Ahead 300 successfully achieved its co-primary endpoints of sensitivity and specificity in distinguishing CT-positive from CT-negative patients, showing improved performance over the Ahead 200, a high negative predictive value (NPV), and good repeatability and reproducibility. The addition of an "Equivocal Zone" for structural injury classification aims to reduce false negatives and provide more nuanced information for clinical decision-making.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the "Equivocal Zone" in the Structural Injury Classification specifically impact clinical decision-making algorithms or protocols compared to the binary classification of the Ahead 200?; What specific quantitative EEG (QEEG) features (e.g., power in specific bands, coherence between particular electrode pairs, fractal dimension characteristics) are most heavily weighted in the Ahead 300's algorithm for deriving the Structural Injury Classification and the Brain Function Index?; While the document states improved accuracy, what are the specific reported sensitivity, specificity, and negative predictive value (NPV) percentages for the Ahead 300 in distinguishing CT-positive from CT-negative structural brain injuries in the B-AHEAD III trial?; How does the EEG Brain Function Index (BFI) quantitatively scale with the severity of functional impairment, and what established clinical or neuroimaging correlates support its interpretation beyond Glasgow Coma Scale (GCS) scores?; Considering the device integrates EEG analysis, cognitive tests, and clinical assessment tools, are there any studies or guidelines on how clinicians should weigh or reconcile potentially discordant results from these different modalities when making a diagnosis or management plan?